The immune microenvironment after neoadjuvant therapy compared to upfront surgery in patients with pancreatic cancer.

ABSTRACT:

Background

Patients with resectable and borderline resectable pancreatic ductal adenocarcinoma increasingly receive neoadjuvant therapy prior to surgery. However, the effect of neoadjuvant therapy on the immune microenvironment remains largely unknown. We analyzed the immune microenvironment in pancreatic cancer tumor tissue samples from patients treated with neoadjuvant therapy compared to patients after upfront surgery to gain knowledge about the immunological environment after therapy.

Methods

Multispectral imaging was performed on tissue from resected specimens from patients with PDAC who underwent upfront surgery (n = 10), neoadjuvant FOLFIRINOX (n = 10) or gemcitabine + radiotherapy (gem-RT) (n = 9) followed by surgery. The samples were selected by a dedicated pancreas

SUBMITTER: Zwart ES 

PROVIDER: S-EPMC10603010 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature